Drugs / IODOMETOMIDATE I-123, R-
IODOMETOMIDATE I-123, R-
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00454103 | Mar 2007 → Dec 2008 | adrenal cortex carcinoma | University of Wuerzburg | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IODOMETOMIDATE I-123, R- | ChEMBL registry synonym — accepted as the source's own label CHEMBL260402 ↗ |
| Known as | (r)-4-(123i)iodometomidate | ChEMBL registry synonym — accepted as the source's own label CHEMBL260402 ↗ |
| Known as | 123i-imto | ChEMBL registry synonym — accepted as the source's own label CHEMBL260402 ↗ |
| Known as | 123I-Iodometomidate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454103 ↗ |
| Known as | Imto i-123 | ChEMBL registry synonym — accepted as the source's own label CHEMBL260402 ↗ |
| Modality | Diagnostic / imaging agent | “In our project we evaluate 123I-Iodometomidate which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.” NCT00454103 ↗ |